Reports
Diabetes Devices Market Size, Share & Growth Analysis, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Diabetes Devices Market Summary
The global diabetes devices market size was valued at USD 33.32 billion in 2025. The market is projected to grow from USD 36.00 billion in 2026 to USD 67.39 billion by 2034, exhibiting a CAGR of 8.1% during 2025–2034.
Market Statistics
Key Takeaways
- North America dominated the global market with 40.0% revenue share in 2025. This is attributed to the increasing aging population and rising prevalence of diabetes.
- The Asia Pacific diabetes devices industry is expected to register a significant CAGR of 9.0% during the forecast period. The presence of major market players and increasing prevalence of diabetes boost the growth.
- The insulin delivery devices segment is expected to witness CAGR of 8.0%. This is driven by rising technological advancements, such as insulin patches, pumps, and automated insulin delivery (AID) systems.
- The blood glucose monitoring (BGM) devices segment held 45.0% share in 2025. The growth is fueled by their affordability and precision in determining the body's glucose level.
- The hospital pharmacies segment held the largest market share of 50.0% in 2025. It is attributed to the growing use of continuous glucose monitoring devices for outpatient monitoring and ICU patients in hospitals.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Increasing prevalence of diabetes propels the demand for insulin delivery devices and continuous glucose monitoring systems.
- Rising awareness of early diabetes management and self-monitoring boosts the adoption of advanced diabetes care devices.
- Limited reimbursement policies in developing regions and high costs of advanced diabetes devices hinder market growth.
- Expanding integration of smartphone connectivity, AI, and digital health platforms will create opportunities for smart diabetes management solutions.
- Use of wearable and minimally invasive glucose monitoring devices transforms patient convenience and treatment compliance. It propels the market expansion.
AI Impact on the Diabetes Devices Market
- Artificial intelligence (AI) enhances continuous glucose monitoring (CGM) systems. It enables real-time glucose trend analysis and predictive alerts.
- AI-enabled insulin pumps and closed-loop delivery systems automate insulin dosing. They also improve glycemic control and reduce human intervention.
- Machine learning (ML) algorithms support personalized diabetes management. It analyzes patient lifestyle, diet, activity, and glucose patterns.
- AI-driven analytics help in early detection of hypoglycemia and hyperglycemia risks. They are used to reduce diabetes-related complications and hospitalizations.
What are Diabetes Devices?
Diabetes devices are medical instruments used to monitor and manage blood sugar levels in individuals suffering from diabetes. These devices aid in maintaining glucose control, preventing complications, and enhancing overall quality of life.
Unhealthy lifestyles, aging, and obesity are among the crucial factors driving the diabetes devices market expansion. As per studies done by the NCBI, obesity is the major cause of diabetes. According to the National Institutes of Health in January 2024, obesity and excess body fat, especially around the abdomen, are strongly linked to type 2 diabetes. Accumulating too much fat can lead to insulin resistance, where the body fails to respond effectively to insulin, complicating blood sugar regulation and increasing the risk of type 2 diabetes. The study emphasizes the importance of weight management and reducing body fat as key preventive measures. It also highlights the role of a healthy lifestyle, including regular blood sugar management using diabetes devices and a balanced diet, in reducing the risk and effectively managing diabetes. Thus, the rising prevalence of diabetes due to the increasing obese population drives the market growth.
To Understand More About this Research: Download Sample Report
The growing demand for diabetes devices is being fueled by their ability to reduce hospital stays and mortality rates among diabetic patients. These devices allow for continuous monitoring and management of blood sugar levels, empowering patients to proactively address their condition and avoid severe complications that often require extended hospitalization. By enabling timely adjustments to treatment regimens, diabetes devices contribute to improved disease management and outcomes, ultimately enhancing the quality of life for individuals affected by diabetes. The increasing adoption of diabetes devices highlights their crucial role in improving patient care and well-being. In February 2023, Abbott launched the FreeStyle Libre 3 system, which offers real-time continuous glucose monitoring with the world's smallest sensor, improving diabetes management accuracy and convenience.
Market Dynamics
Rising Diabetes Prevalence in Developing Economies
The prevalence of diabetes is rising globally, with significant increases observed in developing economies such as China and India. This is mainly driven by the rapid urbanization and growth of sedentary lifestyles. Changes in lifestyle and diet are also associated with urban living, which contributes to the increasing rates of diabetes cases in these regions.
As of March 2024, the World Health Organization (WHO) estimates that 77 million adults in India have type 2 diabetes, with nearly 25 million being prediabetic. Alarmingly, over half of those suffering from diabetes in India are unaware of their condition. Thus, the increasing prevalence of diabetes in emerging economies propels the diabetes devices market growth.
Technological Advancements in Diabetes Devices
Continuous innovation in diabetes device technology is improving safety, bioanalytical performance, wearing duration, bio-compatibility, and other clinical features. These advancements enable patients to understand their condition better and make informed decisions about controlling their blood sugar levels. To fulfill the rising demand for advanced diabetes devices, market players are launching innovative products. For instance, in March 2024, Dexcom announced the launch of the very first CGM system in the market, which can be connected directly to the Apple Watch. Additionally, Afon Technology, a medical device manufacturer, focuses on developing a noninvasive, continuous blood glucose monitor named Glucowear to track and record changes in blood glucose levels. Thus, rising technological advancements in diabetes devices are leading to the diabetes devices market expansion.
What are Future Trends in Diabetes Device Market?
The diabetes devices industry is expected to witness strong growth in the coming years. Rising adoption of continuous glucose monitoring (CGM) systems and advanced insulin delivery devices will drive the growth. There are increasing technological advancements in wearable and non-invasive monitoring solutions. They are improving patient comfort, convenience, and treatment adherence. Also, integration of AI, mobile health applications, and digital healthcare platforms is rising in the market. It will enhance real-time diabetes management and personalized care. The growing prevalence of diabetes and increasing emphasis on preventive healthcare will propel the demand for smart and connected diabetes devices.
Segment Analysis
Diabetes Devices Market Assessment by Type Insights
The global diabetes devices market segmentation, based on type, includes BGM devices, continuous glucose monitoring devices, and insulin delivery devices. The insulin delivery devices segment is expected to grow at a CAGR of 8.0%. This is attributed to significant technological advancements, such as insulin patches, pumps, and automated insulin delivery (AID) systems. These advancements enhance the management of diabetes by providing various options for insulin administration, addressing the needs of a large global diabetic population.
In May 2023, Medtronic announced that it had acquired EOFlow, a South Korean company renowned for its EOPatch wearable insulin patch. The acquisition is intended to improve Medtronic's diabetes management offerings by integrating EOFlow's technology with Medtronic's advanced continuous glucose monitoring and insulin delivery systems.
The blood glucose monitoring (BGM) devices segment held 45.0% share in 2025. The growth is attributed to factors such as the affordability of BGM devices and their precision in determining the body's glucose level. Moreover, technological advancements and the introduction of creative, integrated solutions are causing businesses to introduce affordable, advanced, and user-friendly items.
Comparison Matrix: CGM vs Self-Monitoring Blood Glucose (SMBG)
| Parameter | Continuous Glucose Monitoring (CGM) | Self-Monitoring Blood Glucose (SMBG) |
| Monitoring Type | Provides continuous real-time glucose tracking throughout the day | Provides periodic glucose readings at specific times |
| Method | Uses wearable sensors placed on the body | Uses finger-prick blood tests with glucometer strips |
| Data Availability | Offers trend analysis, alerts, and glucose patterns | Provides single-point glucose measurements |
| Patient Convenience | Minimally invasive with reduced finger pricks | Requires multiple daily finger-prick tests |
| Connectivity | Often integrated with smartphones, apps, and insulin pumps | Limited digital integration in conventional devices |
| Clinical Benefit | Supports proactive diabetes management and better glycemic control | Useful for routine glucose monitoring and spot checks |
| Cost | Higher initial and maintenance cost | Lower cost and widely accessible |
Diabetes Device Market Outlook by Distribution Channel Insights
The global diabetes devices market, based on distribution channel, is segmented into hospital pharmacies, retail pharmacies, diabetes clinics/centers, online pharmacies, and others. The hospital pharmacies segment led the market with the largest revenue share of 50.0% in 2025. This is due to the high volume of patients and the availability of new innovative products. Further, the rising use of continuous glucose monitoring devices for outpatient monitoring and ICU patients in hospitals contributes to the growth of the segment.
The retail pharmacies segment is expected to register a significant CAGR of 8.0% during the forecast period due to their accessibility for patients. These pharmacies offer a range of diabetes care products, including medications, glucose monitoring supplies, insulin delivery systems, and over-the-counter items. Stocking decisions are influenced by physician and patient preferences, profit margins, and insurance coverage.
Regional Insights
By region, the study provides the diabetes devices market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the largest revenue share of 40.0% in the global diabetes device market in 2025 due to various factors such as the rising aging population, increasing incidence of diabetes due to lifestyle changes, growing prevalence of obesity, and high costs of treatment.
According to the National Diabetes Report in May 2024, 38.4 million people, or about 11.6% of the US population, have diabetes. Among US adults, 38.1 million people have diabetes, out of which 8.7 million adults are undiagnosed. Additionally, 97.6 million adults have prediabetes, with significant risk factors including smoking, obesity, and high blood pressure.
The Asia Pacific diabetes devices market is expected to register a significant CAGR of 9.0% during the forecast period. This growth is driven by the presence of leading market players and a rising prevalence of diabetes. Additionally, advancements in blood glucose monitoring technology are expected to propel the diabetes device market share of Asia Pacific, enhancing both the accessibility and effectiveness of diabetes management solutions in the region.
In November 2020, Medtronic, an Asia Pacific-based company, introduced the InPen (a smart insulin pen). The pen is integrated with real-time Guardian Connect CGM data. This innovation provides a special combination of real-time glucose monitoring and dose calculation to improve diabetes management for individuals who use multiple daily injections.
Key Players and Competitive Insights
Leading market players are investing heavily in research and development to expand their offerings, which will boost the diabetes devices market growth during the forecast period. Market participants are also undertaking a variety of strategic activities such as innovative product launches, international collaborations, higher investments, and mergers and acquisitions to expand their global footprint. To expand and survive in a more competitive and rising market climate, the diabetes device industry players must offer cost-effective solutions.
The diabetes devices market faces competition from major global players. These players dominate the market with their extensive production capacities and advanced technologies. Competition is further heightened by fluctuating raw material prices, stringent environmental regulations, and the necessity for technological advancements to improve device efficiency. A few major players in the diabetes devices market are Abbott Diabetes Care; B Braun Melsungen AG; Biocorp; DexCom, Inc.; Johnson & Johnson; GlucoModicum; LifeScan Inc.; Medtronic PLC; Molex; Novo Nordisk; Phillips-Medisize; Roche Diabetes Care; Senseonics, Inc.; and Tandem Diabetes Care, Inc.
Johnson & Johnson offers a wide range of medical, pharmaceutical, and consumer products and devices. With a focus on innovation, the company provides solutions for various health needs, including vision care, medical technology, and specialty care. In February 2024, Johnson & Johnson highlighted innovations in the treatment of low vision, an important consideration for diabetes patients, showcasing new advancements that could improve daily life navigation.
Tandem Diabetes Care focuses on offering advanced insulin pumps integrated with smart technology to simplify diabetes management. Collaborating with industry leaders such as Dexcom, Abbott, and Unomedical, the company creates forward-thinking products tailored to the real needs of users, making it a trusted leader in diabetes care. In February 2024, Tandem Diabetes Care launched the Tandem Mobi, the world’s smallest, durable automated insulin delivery system.
List of Key Companies
- Abbott Diabetes Care
- B Braun Melsungen AG
- Biocorp
- DexCom, Inc.
- Johnson & Johnson
- GlucoModicum
- LifeScan Inc.
- Medtronic PLC
- Molex
- Novo Nordisk
- Phillips-Medisize
- Roche Diabetes Care
- Senseonics, Inc.
- Tandem Diabetes Care, Inc.
Industry Developments
- March 2026: Zydus Lifesciences Limited (“Zydus”) announced that it is planning to launch DiasensTM and GlucoLiveTM. These are next-generation CGM devices. The devices combine AI-powered insights and integrated remote care capabilities. (Source: zyduslife.com)
- February 2025: Tandem Diabetes Care, Inc. received U.S. FDA approval for its Control-IQ+ technology for use in adults with type 2 diabetes. The system is powered by a next-generation automated insulin delivery (AID) algorithm and had previously been approved for patients with type 1 diabetes. (Source: tandemdiabetes.com)
Market Segmentation
By Type Outlook
- BGM Devices
- Self-Monitoring Devices
- Blood Glucose Meters
- Testing Strips
- Lancets
- Continuous Glucose Monitoring Devices
- Sensors
- Transmitters
- Receiver
- Self-Monitoring Devices
- Insulin Delivery Devices
- Pumps
- Pens
- Syringes
- Jet Injectors
By Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
- Others
By End Use Outlook
- Hospitals
- Diagnostic Centers
- Homecare
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Diabetes Devices Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 33.32 billion |
| Market Size Value in 2026 | USD 36.00 billion |
| Revenue Forecast by 2034 | USD 67.39 billion |
| CAGR | 8.1% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global diabetes devices market size was valued at USD 33.32 billion in 2025 and is projected to grow to USD 67.39 billion by 2034.
The global market is projected to register a CAGR of 8.1% during the forecast period.
North America dominated the global market with 40.0% revenue share in 2025.
A few key players in the market are Abbott Diabetes Care; B Braun Melsungen AG; Biocorp; DexCom, Inc.; Johnson & Johnson; GlucoModicum; LifeScan Inc.; Medtronic PLC; Molex; Novo Nordisk; Phillips-Medisize; Roche Diabetes Care; Senseonics, Inc.; and Tandem Diabetes Care, Inc.
The insulin delivery devices segment is expected to witness CAGR of 8.0%.
The hospital pharmacies segment held the largest market share of 50.0% in 2025.
Download Sample Report of Diabetes Devices Market
Please fill out the form to request a customized copy of the research report.
